Immunome/$IMNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunome
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Ticker
$IMNM
Sector
Primary listing
Employees
177
Headquarters
Website
Immunome Metrics
BasicAdvanced
$2.4B
-
-$2.43
2.20
-
Price and volume
Market cap
$2.4B
Beta
2.2
52-week high
$27.65
52-week low
$5.15
Average daily volume
1.1M
Financial strength
Current ratio
14.687
Quick ratio
14.525
Long term debt to equity
0.608
Total debt to equity
0.608
Profitability
EBITDA (TTM)
-211.647
Gross margin (TTM)
-2,454.19%
Net profit margin (TTM)
-3,059.99%
Operating margin (TTM)
-3,084.76%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-28.98%
Return on equity (TTM)
-52.09%
Valuation
Price to revenue (TTM)
264.155
Price to book
3.74
Price to tangible book (TTM)
3.74
Price to free cash flow (TTM)
-8.864
Free cash flow yield (TTM)
-11.28%
Free cash flow per share (TTM)
-2.368
Growth
Revenue change (TTM)
-23.23%
Earnings per share change (TTM)
-51.37%
3-year earnings per share growth (CAGR)
-7.72%
What the Analysts think about Immunome
Analyst ratings (Buy, Hold, Sell) for Immunome stock.
Immunome Financial Performance
Revenues and expenses
Immunome Earnings Performance
Company profitability
Immunome News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunome stock?
Immunome (IMNM) has a market cap of $2.4B as of March 14, 2026.
What is the P/E ratio for Immunome stock?
The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of March 14, 2026.
Does Immunome stock pay dividends?
No, Immunome (IMNM) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Immunome dividend payment date?
Immunome (IMNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunome?
Immunome (IMNM) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.